Beta-Blocker Influences on Inflammatory and Neural Responses to Stress

Recruiting now · Phase 4 · Has a placebo group

Conditions studied: Cardiovascular Disease

In brief

The purpose of this study is to map the neural and molecular mechanisms underlying psychological stress-induced changes in inflammation which could reveal new targets for intervention to reduce the risk of cardiovascular disease.

Key facts

Study ID

NCT06263452

Run by

University of North Carolina, Chapel Hill

People needed

120

Starts

2024-05-01

Expected to finish

2026-05-01

Last updated by the study team

2025-10-29

Who can join

Age: 18 and older, up to 30. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Ages 18-30 years
• Right-handed
• Fluent in English reading, writing, and speaking at least at a 10th grade level
• Body mass index (BMI) less than or equal to 35 kg/m\^2

You may not qualify if…

• Assessed as screening, reassessed at Session I:
• Non-removeable metal devices/implants/objects in the body
• Severe claustrophobia (assessed by self-report)
• Currently pregnant
• Left-handed
• Body mass index (BMI) greater than 35 kg/m\^2
• History of fainting spells or any heart condition
• History of or present low resting heart rate (< 60 BPM) and/or low blood pressure (systolic blood pressure < 80mmHg)
• Self-reported physical illnesses: diabetes, cardiovascular diseases, high blood pressure, inflammatory bowel diseases, rheumatoid arthritis, asthma, autoimmune disease, Crohn's disease, ulcerative colitis, lupus
• Any self-reported diagnosed mental illness
• Current use of prescription medications (except hormonal contraceptives)
• Current or recent regular nicotine/tobacco use (cigarettes, e-cigarettes, vape, chewing tobacco, nicotine gum)
• Current regular (daily or almost daily) recreational drug use = 4 or more times per week
• Instructed against during Session I, reassessed at Session II:
• Received any vaccine within the past two weeks
• Severe sleep disturbance (3-4 hours of sleep loss) the night before Session II
• Vigorous physical activity on the day of Session II
• Acute illness or allergy symptoms on the day of Session II
• Usage of over-the-counter medications on the day of Session II
• Usage of recreational drugs within 48 hours of Session II
• Usage of alcohol on the day of Session II

Where it is running

• Social Neuroscience and Health Laboratory — Chapel Hill, North Carolina, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.